Percutaneous Nerve Evaluation Trial Time
RecruitingNCT06226220Phase: NAStarted 2023-12-10
Summary
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to pla
Eligibility
Sex
FEMALE
Min Age
18 Years
Max Age
None
Locations
University of ChicagoChicago, Illinois, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT06226220